|[January 06, 2014]
Research and Markets: Research Report on China Antidiabetic Drug Market, 2014-2018
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/z2nwrv/research_report)
has announced the addition of the "Research
Report on China Antidiabetic Drug Market, 2014-2018" report to
In 2013, the diabetes prevalence rate of grown-ups aged in 20 to 79 was
8.3% in the globe. The number of sufferers reached 382 million. 80% of
the patients lives in low to medium income countries. Meanwhile, the
number of sufferers in these countries in increasing. The number of
global diabetes sufferers is expected to be 592 million by 2035. In the
current sufferer group, about 175 million people (46%) are not diagnosed
or treated. In 2013, the global IGT prevalence rate was 6.9% and the
number of sufferers was 316 million. The number is expected to be 474
million by 2035.
In 2013, there were 5.1 million people died from diseases related to
diabetes, accounting for 8.4% of the total death number in the globe.
The expenditure on diabetes reached USD 548 billion in the world,
accounting for 11% of global medical treatment expenditure. The
expenditure on diabetes related medical treatment will be USD 627.3
billion by 2035. Diabetes is growing prevalent in China and other
developing countries, which is a heavy burden to the society and economy.
In 2013, the revenue of global diabetes treatment market exceeded USD 40
billion. The CAGR is expected to be 5% or more in next few years.
As China's society is further aging and obesity caused by improved
living level and unhealthy lifestyle is increasing, the prevention and
cure to diabetes become more difficult. The prevalence rate of diabetes
in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in
2013, which become the third chronic disease threatening the health of
The number of diabetes sufferers of China ranks the first in the world.
In 2013, the number exceeded 110 million. Meanwhile, there are more than
400 million people in the diabetes prophase so the number will increase
high in the next 10 years. The under-control rate of grown-up diabetic
sufferers accepting treatment is lower than 40% for lacking medical care.
There are many antidiabetic drug varieties on China market, of which
oral hypoglycemic drugs and insulin dominate the market. While new
antidiabetic drugs like DPP-4 inhibitor, GLP-1 agonist, SGLT-2
inhibitor, etc. become hotspots in the globe, the classic drugs like
Acarbose, Metformin, etc. still occupy most market share in China.
As the prevalence rate is growing and the living level and medical care
level are improved, the market size of antidiabetic drugs is enlarged in
China. In 2013, the market size exceeded CNY 20 billion. The CAGR in
2009-2013 exceeded 17%. CRI (News - Alert) estimates the CAGR of China antidiabetic
drug market size will keep 15%. For global pharmaceutical enterprises,
they will find huge market opportunities in China.
Through this report, the readers can acquire the following
- instance status of diabetes
- Supply and demand of China antidiabetic drugs
- Market status of sub-varieties of antidiabetic drugs
- Competition status of China antidiabetic drug market
- Market opportunities of antidiabetic drugs in China
Key Topics Covered:
1. Overview on Diabetes
2 Therapies on Diabetes and Antidiabetic Drugs, 2009-2013
3 Major Antidiabetic Drugs Applied in Clinic in China, 2009-2013
4 Analysis on China Antidiabetic Drug Market, 2009-2013
5 Major Manufacturing Enterprises (Totals 15-20) in China Antidiabetic
Drug Market, 2009-2013
6 Prospect of Global and China Antidiabetic Drug Market, 2014-2018
- Eli Lilly and Company
- Novo Nordisk (China) Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/z2nwrv/research_report
[ Back To TMCnet.com's Homepage ]